What Multiple Large Trials Show About Heart Risks in Men Using TRT

What Multiple Large Trials Show About Heart Risks in Men Using TRT

The TRAVERSE trial, a large randomized, double-blind, placebo-controlled study, found that testosterone-replacement therapy did not increase major adverse cardiovascular events compared with placebo. Among 5,246 men aged 45 and older with hypogonadism and elevated cardiovascular risk, the primary outcome occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78-1.17) over a mean follow-up of 22 months [1][2].

These results, published in 2023, directly examined a safety question first flagged by the FDA in 2015, when the agency required labeling updates citing possible increased risk of heart attack and stroke based on earlier evidence [3]. The trial forms the centerpiece of a growing body of recent randomized controlled data that regulators and professional societies are reviewing to refine understanding of testosterone therapy’s cardiovascular profile.

What this means

The synthesized data from TRAVERSE and related large randomized trials indicate that testosterone replacement therapy, when used at approved doses in middle-aged and older men with confirmed hypogonadism and high cardiovascular risk, is associated with neutral cardiovascular event rates relative to placebo over roughly two years. This evidence shifts the conversation from earlier observational signals and the FDA’s 2015 caution toward Level-1 data that show no confirmed increase in major adverse cardiovascular events in the studied populations [1][3]. The findings apply most clearly to men similar to those enrolled—older adults already at elevated heart risk—rather than to broader or off-label use.

Primary Cardiovascular Endpoint in the TRAVERSE Trial

The TRAVERSE trial’s primary endpoint was time to first occurrence of a major adverse cardiovascular event, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke [1].

Event rates were nearly identical between groups, producing a hazard ratio that crossed unity and did not meet statistical criteria for harm [1]. The trial registry confirms the prespecified statistical analysis plan and the use of an independent cardiovascular events adjudication committee to maintain objectivity [2].

How Recent RCTs Compare to Earlier Data and FDA Communications

The FDA’s 2015 safety communication required manufacturers to update testosterone product labeling after some observational studies and smaller trials suggested possible cardiovascular risk, particularly in older men using the medicines for age-related testosterone decline [3].

Subsequent large-scale randomized controlled trials, including TRAVERSE, were designed specifically to test that hypothesis with more rigorous methods. The 2023 findings have not replicated the increased-risk signal seen in earlier non-randomized reports, leading to a consensus that testosterone replacement appears cardiovascularly neutral in appropriately selected hypogonadal men at high cardiovascular risk when used within labeled parameters [1][3].

Populations Evaluated Across the Trials

TRAVERSE enrolled 5,246 men with documented hypogonadism, preexisting cardiovascular disease or elevated risk, and a mean age around 65 years [2].

This population reflects men with substantial comorbidity rather than younger, healthier individuals or those with only mild age-related testosterone reductions. The trial’s design therefore provides high-quality safety data for one important real-world group while leaving open questions about extrapolation to others [1][2].

Secondary Signals Noted in the Research

Secondary cardiovascular endpoints, including heart failure and other vascular outcomes, showed patterns consistent with the primary endpoint. The trial also tracked known effects of testosterone such as changes in hematocrit and prostate-specific antigen, which were monitored per standard clinical practice [1].

Professional societies continue to emphasize appropriate patient selection, baseline evaluation, and ongoing laboratory monitoring in clinical use.

Limitations

The TRAVERSE trial primarily enrolled older men (mean age ~65) with significant cardiovascular risk or disease; generalizability to younger hypogonadal men or those without CV comorbidity is limited. The relatively short median follow-up (22 months) may not capture longer-term atherosclerotic or heart-failure outcomes. Use of topical gel formulation means results may not fully extrapolate to injectable or oral testosterone preparations [1][2].